214 related articles for article (PubMed ID: 31964218)
21. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.
Verdanet E; Dereure O; René C; Tempier A; Benammar-Hafidi A; Gallo M; Frouin E; Durand L; Gazagne I; Costes-Martineau V; Cacheux V; Szablewski V
Histopathology; 2017 Oct; 71(4):648-660. PubMed ID: 28594133
[TBL] [Abstract][Full Text] [Related]
22. Follicle center lymphoma is associated with significantly elevated levels of BCL-6 expression among lymphoma subtypes, independent of chromosome 3q27 rearrangements.
Jardin F; Buchonnet G; Parmentier F; Contentin N; Leprêtre S; Lenain P; Picquenot JM; Laberge S; Bertrand P; Stamatoullas A; D'Anjou J; Tilly H; Bastard C
Leukemia; 2002 Nov; 16(11):2318-25. PubMed ID: 12399978
[TBL] [Abstract][Full Text] [Related]
23. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
24. [Molecular abnormalities in lymphomas].
Delsol G
Bull Cancer; 2010 Nov; 97(11):1347-64. PubMed ID: 21084243
[TBL] [Abstract][Full Text] [Related]
25. Bcl-2 rearrangements with breakpoints in both vcr and mbr in non-Hodgkin's lymphomas and chronic lymphocytic leukaemia.
Merup M; Spasokoukotskaja T; Einhorn S; Smith CI; Gahrton G; Juliusson G
Br J Haematol; 1996 Mar; 92(3):647-52. PubMed ID: 8616030
[TBL] [Abstract][Full Text] [Related]
26. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
27. Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
Moffitt AB; Dave SS
J Clin Oncol; 2017 Mar; 35(9):955-962. PubMed ID: 28297626
[TBL] [Abstract][Full Text] [Related]
28. Mutations of the 5' noncoding region of the BCL-6 gene in primary bone lymphomas.
Gianelli U; Ponzoni M; Moro A; Alfano RM; Pellegrini C; Giardini R; Patriarca C; Armiraglio E; Bosari S; Parafioriti A; Coggi G
Ann Hematol; 2003 Nov; 82(11):691-5. PubMed ID: 14513282
[TBL] [Abstract][Full Text] [Related]
29. Recurrent mutations in genes involved in nuclear factor-κB signalling in nodal marginal zone lymphoma-diagnostic and therapeutic implications.
van den Brand M; Rijntjes J; Hebeda KM; Menting L; Bregitha CV; Stevens WB; van der Velden WJ; Tops BB; van Krieken JH; Groenen PJ
Histopathology; 2017 Jan; 70(2):174-184. PubMed ID: 27297871
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo.
Schmitt CA; Lowe SW
Blood Cells Mol Dis; 2001; 27(1):206-16. PubMed ID: 11358381
[TBL] [Abstract][Full Text] [Related]
31. p53, bcl-2 and bax abnormalities in non-Hodgkin's lymphomas of the head and neck.
Miyauchi M; Higashikawa K; Sugiyama M; Harada T; Sasaki N; Ishikawa T
J Oral Pathol Med; 2000 Apr; 29(4):180-5. PubMed ID: 10766396
[TBL] [Abstract][Full Text] [Related]
32. Targeting BCL-2 in B-cell lymphomas.
Davids MS
Blood; 2017 Aug; 130(9):1081-1088. PubMed ID: 28724540
[TBL] [Abstract][Full Text] [Related]
33. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.
Tibiletti MG; Martin V; Bernasconi B; Del Curto B; Pecciarini L; Uccella S; Pruneri G; Ponzoni M; Mazzucchelli L; Martinelli G; Ferreri AJ; Pinotti G; Assanelli A; Scandurra M; Doglioni C; Zucca E; Capella C; Bertoni F
Hum Pathol; 2009 May; 40(5):645-52. PubMed ID: 19144384
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.
Behdad A; Bailey NG
Surg Pathol Clin; 2016 Mar; 9(1):41-54. PubMed ID: 26940267
[TBL] [Abstract][Full Text] [Related]
35. BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
Butler M; Corbally N; Dervan PA; Carney DN
Br J Cancer; 1997; 75(11):1641-5. PubMed ID: 9184180
[TBL] [Abstract][Full Text] [Related]
36. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups.
Marafioti T; Copie-Bergman C; Calaminici M; Paterson JC; Shende VH; Liu H; Baia M; Ramsay AD; Agostinelli C; Brière J; Clear A; Du MQ; Piccaluga PP; Masir N; Nacheva EP; Sujobert P; Shanmugam K; Grogan TM; Brooks SP; Khwaja A; Ardeshna K; Townsend W; Pileri SA; Haioun C; Linch D; Gribben JG; Gaulard P; Isaacson PG
Histopathology; 2013 May; 62(6):860-75. PubMed ID: 23509938
[TBL] [Abstract][Full Text] [Related]
37. Expression of Myc target gene mina53 in subtypes of human lymphoma.
Teye K; Arima N; Nakamura Y; Sakamoto K; Sueoka E; Kimura H; Tsuneoka M
Oncol Rep; 2007 Oct; 18(4):841-8. PubMed ID: 17786344
[TBL] [Abstract][Full Text] [Related]
38. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
39. Double hit and double expressors in lymphoma: Definition and treatment.
Riedell PA; Smith SM
Cancer; 2018 Dec; 124(24):4622-4632. PubMed ID: 30252929
[TBL] [Abstract][Full Text] [Related]
40. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma.
Child FJ; Russell-Jones R; Woolford AJ; Calonje E; Photiou A; Orchard G; Whittaker SJ
Br J Dermatol; 2001 Apr; 144(4):735-44. PubMed ID: 11298531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
